desitin arzneimittel gmbh desitin pharma limited desitin arzneimittel...

COMPANY PROFILE

COMPETENCE IN CNSDESITIN ARZNEIMITTEL GMBH

DESITIN PHARMA LIMITED

DESITIN ARZNEIMITTEL GMBH

OUR HERITAGE

Medium-sized, specialized

pharmaceutical company

• Founded nearly 100 years ago

in Berlin

• Independent, family-owned, profitable

company, based in Hamburg

• About 300 employees in development,

production, sales, medicine, marketing

and administration

• Established as a specialist in the

field of epilepsy

• Addition of further CNS indications


FULLY INTEGRATED PHARMACEUTICAL COMPANY

Quality ControlProduction

Head Office

“White House”

Warehouse/Dispatching


Incorporating Sales & Marketing, commercial, medical affairs and regulatory, full manufacturing and production lines and comprehensive distribution

STRONG REPUTATION IN CNS

COMPANIES WITH THE HIGHEST EXPERTISE

IN EPILEPSY IN GERMANY- 2013

Source: Medupha, 2013 (n=100 neurologists)

0

10

20

30

40

50

1 2 3 4 5 6 7 8

%

DESITIN


STRONG REPUTATION IN CNS

COMPANIES WITH BEST SERVICE FOR THE

PHYSICIAN - 2013

COMPANIES WITH BEST SERVICE FOR

EPILEPSY PATIENTS IN GERMANY - 2013


0

10

20

30

40

50

60

1 2 3 4 5 6 7 8

%

Source: Medupha, 2013 (n = 100 neurologists)

0

10

20

30

40

50

1 2 3 4 5 6 7 8

%

DESITIN

DESITIN

A SELECTION OF PRODUCTS

N3A/N4A Broad range of standard therapeutics

N3A: Epilepsy • N4A: Parkinson’s Disease M03AX: Dystonia •

L01XD04: Sensitizers used in photodynamic/radiation therapy

Antiepileptic with innovative

formulation

N3A

Innovative presentation

of a well-known antiepileptic

N3A

Innovative presentation

of a well-known antiepileptic

N3A

Antiepileptic drug (Orphan)

for severe myoclonic epilepsy

(Dravet Syndrome)

N3A

Antiparkinson drug (non-

ergoline dopamine agonist)

N4A

Indicated for the treatment

of dystoniaM03AX

Indicated for the treatment

of actinic keratosisL01XD04


Only Orfiril® long and Levitiracetam Desitin® are marketed in the UK and under different brand names. Orfiril® long is marketed in the UK as Episenta® (sodium valproateprolonged release), Levetiracetam Desitin® is marketed in the UK as Desitrend® (levetiracetam). All other brands are not currently available in the UK.

TOTAL TURNOVER (Business Year: Oct 1st to Sep 30th)

International

Germany

0

10

20

30

40

50

60

70

80

90

100

2007/08 2008/09 2009/10 2010/11 2011/12 2012/13

Mil

lio

ns

€

96.5

7783

8993.5

99.5


TURNOVER ACCORDING TO AREAS

Germany68%

Northern Europe11%

Western Europe8%Eastern Europe

10%

ROW3%

Fiscal Year 2012/13Total Turnover: 99.5 million €


EUROPEAN TERRITORIES

DESITIN – A European CNS Force

KEY COUNTRIES(with own affiliates)

Germany, Norway, Denmark, Sweden,

Switzerland, Czech Republic, Slovakia,

Romania, UK, Estonia, Moldova

PARTNER COUNTRIES(with local distributors)

Austria, Belgium, Croatia, Finland, France,

Hungary, Iceland, Netherlands, Poland,

Portugal, Spain, Turkey


DEDICATED TO EPILEPSY

• Offices located in Guildford,

Surrey

• The UK affiliate is a

fully-owned subsidiary of

Desitin Arzneimittel GmbH


• Product range for treatment of

epilepsy in a variety of different

formulations.

PRODUCTS AND FORMULATIONS


A VALUED PARTNER

• Reliable service-orientated partner

to physicians, pharmacists, patients

and their families

• Highly ethical and professional

company

• Member of the Ethical Medicines

Industry Group (EMIG)

• Open-minded mentality, flexible

in terms of business models and

innovative approaches


• ...with Key Opinion Leaders in key

University Hospitals and Clinical

Commissioning Groups (CCGs)

• Responsive to requests from

clinicians, specialist nurses,

pharmacists and patients

• Highly motivated – excellent team

spirit combined with hard-working,

positive ‘can-do’ attitude

• Excellent track record in innovative

drug delivery forms and new

Desitin product launches

PARTNERSHIP OF CHOICE...

Neurology

Paediatric

Psychiatry


THERAPY FOCUS & TARGETS

• Major therapeutic areas:

• Neurology

• Epilepsy

• Target KOLs and doctors:

• Current Field Force capacity

up to 7,000 calls per annum

• Regular field visits to:

• 200 Neurologists

• 60 Neuro-paediatricians

• 64 Epileptologists

• 250 Epilepsy Specialists Nurses

• 100 Hospital/CCG Pharmacists

• Regular management visits

to key stakeholders


148.673

246.797

328.811

489.111

585.685

769.127

892.918

989.643

£1,120.640

1,231,157

1,373,381

1,559,050

0

200

400

600

800

1000

1200

1400

1600

1800

Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13

Valu

e (

£’0

00s)

SALES HISTORY (£’000s)


NEW BUSINESS TARGETS

WE ADD VALUE IN THE

PROMOTION OF

SPECIALTY PRODUCTS

IN THE FIELD OF

EPILEPSY

WE SEEK NEW BUSINESS

OPPORTUNITIES IN

NEUROLOGY


TARGET GROUPS

• Neurologists

• Psychiatrists

• Paediatric specialists

• Neurosurgeons

• Hospital pharmacists

• CCG stakeholders


• In-licensing with exclusive rights

for sale

• Acquisition of products with potential

for sales growth or stabilisation

• Distribution Agreement (including

Marketing & Sales rights)

• Selected products

• Complete portfolio

• Co-Promotion

• Co-Marketing

NEW BUSINESS – POSSIBLE CO-OPERATION MODELS


www.desitin.co.uk

Mark InkerUK Managing Director

e-mail: [email protected]

Tel: +44 7771 870 190 (mobile)

Office Address:

Desitin Pharma Limited,

Unit 50,

Surrey Technology Centre,

40 Occam Road,

Surrey Research Park,

Guildford, Surrey GU2 7YG

CONTACTS


desitin arzneimittel gmbh desitin pharma limited desitin arzneimittel...

Documents